Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track ADCT with free AI briefings, catalyst countdowns, and dilution alerts.

ADCT — ADC Therapeutics SA

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$231M Cash on Hand

22.8mo Cash Runway

5.6% Short Interest

🧪 Upcoming Trial Catalysts

2026-06-30 · Phase 3 — Active Trial — Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Ca
2026-07-01 · N/A — Recruiting — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic
2026-12-11 · Phase 2 — Recruiting — A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Express
2026-12-31 · Phase 1 — Upcoming Trial — First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
2026-12-31 · Phase 1 — Recruiting — First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
2027-01-29 · Phase 3 — Active Trial — Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Ca

💰 Cash Runway & Dilution Risk

ADCT holds $231M in cash and burns about $30.4M/quarter from operations, giving an estimated runway of 22.8 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for ADCT free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-06-03	Coughlin Timothy	Purchase	$0
2026-06-03	Squarer Ron	Purchase	$0
2026-06-03	Sandor Victor	Purchase	$0
2026-06-03	BIZZARI JEAN-PIERRE	Purchase	$0
2026-06-03	Azelby Robert	Purchase	$0

Get the full ADCT picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for ADCT and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z